Abstract:We have read with great interest of the recently published article entitled “Effect of targeted therapy on circulating progenitor cells in precapillary pulmonary hypertension” by García-Lucio J et al. [ [1] Garcia-Lucio J. Tura-Ceide O. Del Pozo R. Blanco I. Pizarro S. Ferrer E. et al. Effect of targeted therapy on circulating progenitor cells in precapillary pulmonary hypertension. Int. J. Cardiol. 2017; 228: 238-243 Abstract Full Text Full Text PDF PubMed Scopus (7) Google Scholar ]. In this study, the number of circulating endothelial progenitor cells (EPC) is lower in naïve pulmonary artery hypertension (PAH) patients, and treatment of PAH-targeted drugs increased EPC levels in the blood of PAH patients. However, there is no elevation of circulating EPC in chronic thromboembolic pulmonary hypertension patients. Previous reports suggest that the level of circulating EPC is positively correlated with pulmonary artery pressure [ [2] Foris V. Kovacs G. Tscherner M. Olschewski A. Olschewski H. Biomarkers in pulmonary hypertension: what do we know?. Chest. 2013; 144: 274-283 Abstract Full Text Full Text PDF PubMed Scopus (72) Google Scholar ]; moreover, EPC from PAH patients treated with treprostinil showed a more proliferative phenotype and more angiogenic potential [ [3] Smadja D.M. Mauge L. Gaussem P. d'Audigier C. Israel-Biet D. Celermajer D.S. et al. Treprostinil increases the number and angiogenic potential of endothelial progenitor cells in children with pulmonary hypertension. Angiogenesis. 2011; 14: 17-27 Crossref PubMed Scopus (45) Google Scholar ]. Animal study showed that infusion of EPC from monocrotaline-induced murine PAH model increases the pulmonary artery pressure of healthy animals [ [4] Aliotta J.M. Pereira M. Wen S. Dooner M.S. Del Tatto M. Papa E. et al. Bone marrow endothelial progenitor cells are the cellular mediators of pulmonary hypertension in the murine monocrotaline injury model. Stem Cells Transl. Med. 2017; 6: 1595-1606 Crossref PubMed Scopus (16) Google Scholar ]. These may indicate that the reduction of EPC number and dysfunction of EPC are involved in the pathogenesis of PAH; targeted therapy for PAH may decrease pulmonary artery remodeling at least partially through improving the proliferation and function of EPCs. Recent studies showed that modulating intracellular genes or microRNAs is sufficient to improve EPC differentiation and proliferation. Excitingly, gene-enhanced EPC therapy is entering clinical trials for human PAD [ [5] Granton J. Langleben D. Kutryk M.B. Camack N. Galipeau J. Courtman D.W. et al. Endothelial NO-synthase gene-enhanced progenitor cell therapy for pulmonary arterial hypertension: the PHACeT trial. Circ. Res. 2015; 117: 645-654 Crossref PubMed Scopus (102) Google Scholar ]. In conclusion, modulation of EPC proliferation and function may serve as a new strategy for PAH therapy.

Modulation of EPC: A New Hope for Pulmonary Artery Hypertension Treatment